ライフサイエンスコーパス: cardioprotection

1 hages with clodronate abolished CDC-mediated cardioprotection.

2 n nitric oxide (NO) production to potentiate cardioprotection.

3 This is a revolutionary new approach to cardioprotection.

4 ophagy induction might underlie the observed cardioprotection.

5 ed pluripotent stem cells is associated with cardioprotection.

6 on how the citric acid cycle is involved in cardioprotection.

7 se 2beta as the primary molecular target for cardioprotection.

8 nism of endothelial lipase function improves cardioprotection.

9 dation markers and autophagic mechanisms for cardioprotection.

10 onist can restore this aging-related loss of cardioprotection.

11 s also required for autophagy activation and cardioprotection.

12 simultaneously study antitumor activity and cardioprotection.

13 that PI3K is necessary for exercise-induced cardioprotection.

14 acilitate the development of pharmacological cardioprotection.

15 g may be a mechanism for nitroalkene-induced cardioprotection.

16 genes by HDL might link innate immunity and cardioprotection.

17 or understanding the underlying mechanism of cardioprotection.

18 ocardial I/R injury with betaARKct imparting cardioprotection.

19 gesting a novel pharmacological strategy for cardioprotection.

20 ation of proteins plays an important role in cardioprotection.

21 andling and play an important role in female cardioprotection.

22 phagy may provide a novel strategy to confer cardioprotection.

23 application of topical capsaicin, to elicit cardioprotection.

24 ll (RBC) to mediate hypoxic vasodilation and cardioprotection.

25 -sensitive conductance and may contribute to cardioprotection.

26 e show involvement of the K(ATP) channels in cardioprotection.

27 et for sustainable prophylactic induction of cardioprotection.

28 cancer, although these drugs do not provide cardioprotection.

29 vascular nitric oxide species accounting for cardioprotection.

30 gulation of heme oxygenase (HO-1) to provide cardioprotection.

31 osphorylation at its Ser16 site enhances its cardioprotection.

32 ricted expression of iNOS provides sustained cardioprotection.

33 nts an endogenously recruitable mechanism of cardioprotection.

34 essential role of PKG in sildenafil-induced cardioprotection.

35 ther sex differences exist in TNFR2-mediated cardioprotection.

36 ng eNOS activation, which ultimately lead to cardioprotection.

37 properties that contribute to their role in cardioprotection.

38 plays critical roles in atheroprevention and cardioprotection.

39 icits similar effects on S-nitrosylation and cardioprotection.

40 athway, the putative mechanism for aspirin's cardioprotection.

41 n pore is emerging as a central mechanism in cardioprotection.

42 ealing gene expression profile, and mediated cardioprotection.

43 examining mechanisms of volatile anesthetic cardioprotection.

44 cogen synthase kinase-3beta (GSK-3beta), and cardioprotection.

45 ibition of both may achieve further enhanced cardioprotection.

46 ucidating the signaling pathways involved in cardioprotection.

47 the beta2-adrenergic receptor (beta2-AR) in cardioprotection.

48 strate Akt but had no effect on EPO-mediated cardioprotection.

49 re act as humoral transfer factors of RIPC s cardioprotection.

50 ricular myocardium is associated with RIPC s cardioprotection.

51 y partially account for the nitrite-mediated cardioprotection.

52 have truly a chance to benefit from adjunct cardioprotection.

53 s a potential therapeutic target for post-MI cardioprotection.

54 f transcription 5 was associated with RIPC's cardioprotection.

55 an important role in energy homeostasis and cardioprotection.

56 uce greater amounts of NO, thereby affording cardioprotection.

57 caveolae have been found to be critical for cardioprotection.

58 ng ribosome biosynthesis, cell survival, and cardioprotection.

59 t hypercholesterolemia abolishes HDL-related cardioprotection.

60 of PKCdelta-suppressed Mvarphi recapitulates cardioprotection.

61 t might translate into long-term nephro- and cardioprotection.

62 tion, and the development of hypertrophy and cardioprotection.

63 important but previously undescribed role in cardioprotection.

64 tion of both molecular pathways that trigger cardioprotection.

65 ct size, it would be premature to give up on cardioprotection.

66 e IAE was more effective than that of MVT in cardioprotection.

67 nnels play crucial roles in excitability and cardioprotection.

68 SM, yet there are no reports that it confers cardioprotection.

69 ve stimulation (VNS) has been shown to exert cardioprotection.

70 xplored role of S-nitrosylated hemoglobin in cardioprotection.

71 tribution of adenosine in ticagrelor-related cardioprotection.

72 as a critical component in exosome-mediated cardioprotection.

73 n lieu of postconditioning caused equivalent cardioprotection (15.0+/-2.6% infarction), whereas 1 min

74 on and reperfusion has been shown to produce cardioprotection, a phenomenon termed anesthetic-induced

75 ineered mice to test the hypothesis that the cardioprotection afforded by iNOS gene transfer is media

76 The cardioprotection afforded by RhoA was reversed by PKD in

77 100 g/L hemoglobin in anemic animals offers cardioprotection after acute myocardial infarction.

78 Although efficient cardioprotection after HO-1 overexpression has been repo

79 on into the signaling mechanisms involved in cardioprotection after IPC was performed in both uremic

80 and promote cell survival, thereby providing cardioprotection after MI.

81 t and necessary for the resulting late phase cardioprotection against a subsequent ischemia/reperfusi

82 spholipase C-delta1 in TNF receptor-mediated cardioprotection against adriamycin-induced injury was e

83 PHLPP-1 knockdown enhances LIF-mediated cardioprotection against doxorubicin and also protects c

84 on a panel of human cancer cell lines, their cardioprotection against doxorubicin-induced apoptosis i

85 ng sufficient endothelial BH4 is crucial for cardioprotection against hypoxia/reoxygenation injury.

86 Thus, Sestrin2 plays an important role in cardioprotection against I/R injury, serving as an LKB1-

87 PKD as a downstream mediator of RhoA and in cardioprotection against I/R.

88 yocardial hypertrophy and heart failure, and cardioprotection against ischaemia-reperfusion.

89 il, a phosphodiesterase-5 inhibitor, induces cardioprotection against ischemia/reperfusion injury via

90 treatment leads to increased protein SNO and cardioprotection against ischemia/reperfusion injury, su

91 e ischemic stimuli have been shown to elicit cardioprotection against ischemia/reperfusion injury, th

92 ential factor produced by EC, which promotes cardioprotection against ischemic injury.

93 RCS induces cardioprotection against lethal myocardial ischemia that

94 lae and Cav-3 are essential for AS-1-induced cardioprotection against myocardial I/R injury.

95 bition of PI3K abolished the HSPA12B-induced cardioprotection against myocardial I/R injury.

96 odulation of Ca(2)(+) handling provides some cardioprotection against the paradoxical effects of rest

97 This review focuses on mechanisms by which cardioprotection alters mitochondrial proteins and chann

98 ivation of mTOR while Gfat1 deficiency shows cardioprotection and a concomitant decrease in mTOR acti

99 nt bioactive molecule, capable of conferring cardioprotection and a variety of other benefits in the

100 p110alpha) is essential for exercise-induced cardioprotection and delivery of caPI3K vector can impro

101 idate possible mechanisms of nitrite-induced cardioprotection and have implications for nitrite dosin

102 antisense PGC-1alpha prevented DPN-mediated cardioprotection and increase in ATP levels and Tfam but

103 heightened sympathetic activity to aberrant cardioprotection and increased ischemic vulnerability in

104 In addition, the DPN-induced cardioprotection and increased SNO were abolished by tre

105 The importance of the PKCepsilon isozyme in cardioprotection and its relationship to cardioprotectio

106 ects at mitochondria have been implicated in cardioprotection and mitochondria/cytosol fractionation

107 tion occurs in vivo and on its mechanisms of cardioprotection and modulation of energy metabolism.

108 her show that meclizine pretreatment confers cardioprotection and neuroprotection against ischemia-re

109 consistently reduced infarct size indicating cardioprotection and PDE5Is also promote reverse remodel

110 bition of Arg1 in wild-type mice had similar cardioprotection and reduced inflammation after MI as Fo

111 vivo from cardiac biopsies; they confer both cardioprotection and regeneration in acute myocardial in

112 data show an important role for beta2-AR in cardioprotection and support the novel hypothesis that p

113 gatory downstream effector of iNOS-dependent cardioprotection and that NF-kappaB is a critical link b

114 ct relationship of PKG in sildenafil-induced cardioprotection and the downstream targets of PKG remai

115 ion puncture to assess hemodynamic efficacy, cardioprotection, and biomechanics under acute or contin

116 injection (10 mg/kg), hemodynamic efficacy, cardioprotection, and biomechanics were assessed under I

117 is essential for mediating exercise-induced cardioprotection, and if so, whether its activation inde

118 circulatory systems including vasodilation, cardioprotection, and pain transmission.

119 , generates reproducible results, can detect cardioprotection, and provides a mechanism for assessing

120 cal and pharmacological approaches to induce cardioprotection, and their signal transduction pathways

121 ling, contributing to extension of lifespan, cardioprotection, and tumor inhibition.

122 1 as well as 8 paracrine factors involved in cardioprotection, angiogenesis, and stem cell function.

123 During the late phase of cardioprotection, antigen immunomodulatory pathways were

124 Outcomes of cardioprotection are affected by age, sex, comorbidities

125 ional control of pathological remodeling, to cardioprotection arising from caloric restriction.

126 active transdifferentiation, resulting into cardioprotection as indicated by diminished scar formati

127 r activation with apelin peptides results in cardioprotection as noted through positive ionotropy, an

128 s which have previously been associated with cardioprotection, before (baseline)/after RIPC or placeb

129 a qualitatively different genomic profile of cardioprotection between ischemic preconditioning induce

130 dies addressing long-term effects of adjunct cardioprotection beyond infarct size reduction, that is,

131 om numerous successful animal experiments on cardioprotection beyond that by reperfusion to clinical

132 Therefore, cardioprotection beyond that by timely reperfusion is ne

133 Therefore, cardioprotection beyond timely reperfusion is needed.

134 ed the involvement of Cav-3 in AS-1 mediated cardioprotection both in vivo and in vitro.

135 ivates cell signaling pathways and generates cardioprotection but has not been linked to LMP-2 functi

136 nly provide a potential new target for acute cardioprotection but it may also act as an anti-diabetic

137 ssential downstream effector of AKT-mediated cardioprotection but the mechanistic basis for maintenan

138 PCR (A1AR) is a major therapeutic target for cardioprotection, but current agents acting on the recep

139 Gq coupling is required for cardioprotection by an alpha-1A-AR agonist.

140 These results suggest that MnSOD provides cardioprotection by attenuating IR-induced oxidation and

141 cise-induced increase in MnSOD would provide cardioprotection by attenuating IR-induced oxidative mod

142 ardiac muscle survival, substantiating human cardioprotection by cMSCs, and suggesting the cMSC secre

143 Cardioprotection by combined intrahospital RIC and PostC

144 sitive potassium channel in the mechanism of cardioprotection by DZX.

145 Postischemia cardioprotection by EPO required the PI3K pathway but wa

146 Also, cardioprotection by exenatide treatment is independent o

147 carbon metabolism, which could contribute to cardioprotection by generating reduced nicotinamide aden

148 Myocardial ischemia and cardioprotection by ischemic pre-conditioning induce sig

149 potassium channel (mK(ATP)) is implicated in cardioprotection by ischemic preconditioning (IPC), but

150 c function, ischemia-reperfusion injury, and cardioprotection by ischemic preconditioning.

151 Cardioprotection by Klotho in normal mice is mediated by

152 ly at intercalated discs (IDs) and conferred cardioprotection by maintaining normal ID structure and

153 Perioperative cardioprotection by means of gene therapy might improve

154 mechanism of DOX-induced cardiomyopathy and cardioprotection by mitoquinone (Mito-Q), a triphenylpho

155 duration of ischemia can be so that adjunct cardioprotection by postconditioning at reperfusion stil

156 diac mast cells, contributing to IPC-induced cardioprotection by preventing mast cell renin release a

157 Loss of cardioprotection by RIPC during propofol anesthesia depe

158 Cardioprotection by RIPC in pigs causally involves activ

159 l is suggested to be an inhibiting factor of cardioprotection by RIPC, but the underlying mechanism i

160 globin within the target organ abrogated the cardioprotection by rIPC.

161 Cardioprotection by salvage of the infarct-affected myoc

162 thesis that IPC-induced protein SNO provides cardioprotection by shielding cysteine residues from rea

163 The loss of cardioprotection by the mutant Hsp20 was associated with

164 ompound C (AMPK inhibitor) partially blocked cardioprotection by TP, suggesting that both PKC and AMP

165 This loss of cardioprotection by Ucn was also seen in whole hearts fr

166 Cx43 C-terminal binding peptide RRNYRRNY for cardioprotection, circumventing further upstream pathway

167 studies showed that they conferred enhanced cardioprotection compared to adenine or 4-hydroxythioben

168 ense oligonucleotides greatly attenuated the cardioprotection conferred by exercise.

169 on (p < .05), NO increase (p < .05), and the cardioprotection conferred by hypercarbic reperfusion (i

170 s compared to wild-type mice and loss of the cardioprotection conferred by ischemic preconditioning.

171 nce has indicated that it provides long-term cardioprotection; continuous infusions should be elimina

172 f the discussions of the European Union (EU)-CARDIOPROTECTION Cooperation in Science and Technology (

173 dence showing PostC-induced infarct-limiting cardioprotection could be triggered by activation of mul

174 a novel therapeutic strategy for neuro- and cardioprotection, disorders of smooth muscle hyperactivi

175 ata suggest that Pim-1 is a crucial facet of cardioprotection downstream of Akt.

176 reventing no-reflow and conferring secondary cardioprotection during AMI.

177 The METOCARD-CNIC (Effect of Metoprolol in Cardioprotection During an Acute Myocardial Infarction)

178 f the METOCARD-CNIC (effect of METOprolol of CARDioproteCtioN during an acute myocardial InfarCtion)

179 epsilon (PKCepsilon) plays a pivotal role in cardioprotection during cardiac ischemia and reperfusion

180 Dexrazoxane should be considered for cardioprotection during frontline treatment of pediatric

181 se at the remote site of rIPC contributes to cardioprotection during I/R.

182 H2S therapy with SG-1002 resulted in cardioprotection during transverse aortic constriction v

183 yloidogenic protein and the first conferring cardioprotection even in the unfavourable context of ren

184 the PI3K/Akt signaling pathway in TLR4(-/-) cardioprotection following I/R injury.

185 icate ankyrin-B as a molecular component for cardioprotection following ischemia.

186 receptor-beta and consequently contribute to cardioprotection following trauma hemorrhage.

187 medications are becoming essential tools for cardioprotection for patients with diabetes and CVD.

188 We evaluated metallothionein (MT)-mediated cardioprotection from angiotensin II (Ang II)-induced pa

189 e discuss the difficulties in translation of cardioprotection from animal experiments and proof-of-co

190 Dexrazoxane provides long-term cardioprotection from doxorubicin-associated cardiotoxic

191 Thus, TP508 may offer a novel approach in cardioprotection from ischemia-reperfusion injury in dia

192 ion of glycolytic enzymes and Per2-dependent cardioprotection from ischemia.

193 igh-density lipoprotein (HDL) cholesterol in cardioprotection has been questioned by genetic and rand

194 he effect of fluoxetine on mK(ATP)-dependent cardioprotection has implications for the growing use of

195 otein important in insulin sensitization and cardioprotection, has a strong genetic component.

196 Several methods of cardioprotection have shown the ability to limit myocard

197 t contribute to ischemic preconditioning and cardioprotection, high levels of ROS induce structural m

198 us wave was ameliorated only in pigs showing cardioprotection (ie, those undergoing short-duration is

199 Regional hHO-1 gene therapy provides cardioprotection in a pre-clinical porcine ischemia/repe

200 investigated the use of sildenafil-mediated cardioprotection in a rat model of heterotopic cardiac t

201 Cardiosphere-derived cells (CDCs) confer cardioprotection in acute myocardial infarction by disti

202 n of CRP is thus a promising new approach to cardioprotection in acute myocardial infarction, and may

203 echanisms responsible for SF-PreCon mediated cardioprotection in DM mice, cell survival molecules wer

204 ents have been identified that confer robust cardioprotection in experimental animal models of acute

205 We tested the hypothesis that cardioprotection in females is mediated by altered mitoc

206 Spermidine feeding failed to provide cardioprotection in mice that lack the autophagy-related

207 ymphatics promote cardiac growth, repair and cardioprotection in mice.

208 heart by ischemia/reperfusion confers robust cardioprotection in part through induction of the HBP.

209 the safety of one glass of wine per day for cardioprotection in patients at risk for both coronary h

210 rsus NRG, NN has translational potential for cardioprotection in patients with cancer receiving anthr

211 is a potential mediator of exercise-induced cardioprotection in post-MI rats.

212 viable therapeutic approach to enhance late cardioprotection in postischemic heart disease.

213 rresponding to cytotoxicity in the tumor and cardioprotection in the heart.

214 ressing an elusive clinical goal: meaningful cardioprotection in the postreperfusion time period.

215 tion and survival; however, it also imparted cardioprotection in the presence of PKCalpha/beta inhibi

216 unique capacity of (-)-epicatechin to confer cardioprotection in the setting of a severe form of myoc

217 the presence of mRQ with ADR conferred full cardioprotection in these mice.

218 A and EPA omega-3 PUFA that provides maximal cardioprotection in those at risk of CV disease as well

219 tective or a central mediator of adiponectin cardioprotection in vivo remains unknown.

220 yocardial IPC, and SNO is thought to provide cardioprotection, in part, by reducing cysteine oxidatio

221 e of glycogen synthase kinase (GSK)-3beta in cardioprotection, including pre- and postconditioning.

222 opropionyl) glycine during TP also abolished cardioprotection, indicating an involvement of free radi

223 During DM, cardioprotection induced by conventional pre-conditionin

224 mice; genetic deletion of eNOS abrogated the cardioprotection induced by late PC.

225 The conditioning phenomena provide such cardioprotection, insofar as brief episodes of coronary

226 This cardioprotection is associated with a decrease in reperf

227 f failure has led us and others to wonder if cardioprotection is dead.

228 e tested the hypothesis that ERbeta-mediated cardioprotection is induced via up-regulation of PGC-1al

229 er women generally being protected, but this cardioprotection is lost later in life, suggesting a rol

230 uestion of whether post-conditioning-induced cardioprotection is maintained in aging cohorts is unkno

231 One proposed mechanism of cardioprotection is mitochondrial matrix swelling.

232 (eNOS) in ischemic preconditioning (PC) and cardioprotection is poorly understood.

233 Receptor-mediated cardioprotection is triggered by an intracellular signal

234 eutic strategy to target mTORC1 and increase cardioprotection is under intense investigation.

235 novel 5HT2R antagonists, with potential for cardioprotection, liver protection, or central nervous s

236 nd Col14a1, with concomitant upregulation of cardioprotection markers, including COX-2 itself, lipoca

237 s regard, emerging data suggest that optimal cardioprotection may require the combination of additive

238 These results suggest a novel cardioprotection mechanism by Mito-Q during DOX-induced

239 ts reveal a novel gender-specific pathway of cardioprotection mediated by ERalpha and its regulation

240 optimization of tissue-level perfusion, and cardioprotection must be addressed to improve patient ou

241 ferences in the mechanisms of TNFR2-mediated cardioprotection occur by increasing STAT3, SOCS3, and v

242 ockout mice, indicating that the DPN-induced cardioprotection occurs through the activation of ER-bet

243 However, a significant portion of the cardioprotection of adiponectin against MI/R injury was

244 However, the mechanism underlying cardioprotection of Hsp20 and especially the role of its

245 gulation of cyclooxygenase-2 (COX-2) and the cardioprotection of late preconditioning (PC), the role

246 c targets in cardiovascular diseases such as cardioprotection of murine hearts after myocardial infar

247 and XI), we investigated the role of PKB in cardioprotection of the rat and human myocardium, the lo

248 18BP genetically modified stem cells improve cardioprotection over that observed with unmodified stem

249 hol intake can actually provide a measure of cardioprotection, particularly against coronary heart di

250 ession is sufficient and necessary to induce cardioprotection post-MI, thereby highlighting the thera

251 y-ligated rat heart, suggests that AA-driven cardioprotection primarily arises from PPARalpha agonism

252 ent with leptin (0.12 mug/kg i.v.) abolished cardioprotection produced by Goodbelly.

253 in cardioprotection and its relationship to cardioprotection produced by Ucn was assessed using PKCe

254 ) 24 h before ischemia/reperfusion abolished cardioprotection produced by vancomycin treatment.

255 RIPC plasma could not induce cardioprotection (Prop-RIPC: 63% [56-70%] ns vs Prop-Con

256 of the mechanistic basis for Pim-1 mediated cardioprotection provides important insights for designi

257 animal MI models, TG100-115 provided potent cardioprotection, reducing infarct development and prese

258 Red wine may offer increased cardioprotection related to its antioxidant properties.

259 ion in organs remote from the heart provides cardioprotection (remote ischemic conditioning).

260 ly modify ANT1 and that nitroalkene-mediated cardioprotection requires ANT1.

261 Cardioprotection resulting from the absence of HDAC5 or

262 Thus, the cardioprotection seems to correlate to antagonism to het

263 We conclude that IPC-induced miRNAs trigger cardioprotection similar to the delayed phase of IPC, po

264 sue injury, a phenomenon termed sex-specific cardioprotection (SSC).

265 of studies focused on infarct size, only few cardioprotection studies addressed MVO as a therapeutic

266 Previous cardioprotection studies were mainly aimed at protecting

267 m of beta(2)ARs abolished betaARKct-mediated cardioprotection, suggesting that enhanced GRK2 activity

268 unique endogenously recruitable mechanism of cardioprotection that may involve direct modification of

269 st focus on patients who really need adjunct cardioprotection, that is, those with severe haemodynami

270 is review addresses the role of autophagy in cardioprotection, the balance of catabolism and anabolis

271 Adenosine elicits cardioprotection through A1-receptor activation.

272 or mitochondrial STAT3 activation to mediate cardioprotection through better mitochondrial function.

273 ell death through PKA-dependent pathways and cardioprotection through PKA-independent pathways.

274 contributed to the failure of translation of cardioprotection to clinical practice.

275 iew will present an overview of the state of cardioprotection today and provide a roadmap for how we

276 Fluoxetine also blocked cardioprotection triggered by IPC, but did not block pro

277 79 is critical for alternative mitophagy and cardioprotection under energy stress conditions.

278 uated potential mechanisms of H(2)S-mediated cardioprotection using an in vivo model of pharmacologic

279 f SIAH in facilitating NO/netrin-1-dependent cardioprotection, using the DCC receptor.

280 ergic receptor (beta1AR) stimulation confers cardioprotection via beta-arrestin-de pend ent transacti

281 w the importance of L-arginine and BH(4) for cardioprotection via regulation of mitochondrial oxidati

282 )ATSM may provide a therapeutic strategy for cardioprotection via upregulation of antioxidant defense

283 as a Kcnma1 product because NS1619-mediated cardioprotection was absent in Kcnma1 knockout mice.

284 hways, demonstrating that fingolimod-induced cardioprotection was mediated by reperfusion injury salv

285 iNOS-mediated cardioprotection was not abolished by atractyloside.

286 Similar cardioprotection was observed in guinea pig hearts treat

287 Cardioprotection was prevented by a neutralizing antibod

288 he potential mechanisms of O-GlcNAc-mediated cardioprotection, we discuss technical issues related to

289 n kinase (PKG) signaling plays a key role in cardioprotection, we hypothesized that PKG activation wi

290 four conditions, the following hallmarks of cardioprotection were recorded using electrophysiology o

291 ibition of RASSF1A in cardiomyocytes affords cardioprotection, whereas myeloid-specific deletion of R

292 H) and remarkably concordant nitrite-induced cardioprotection, which both followed a complex dose-res

293 lso post-I/R) still demonstrated significant cardioprotection, which suggested a potential protective

294 ting protein S-nitrosylation and its role in cardioprotection will provide us new therapeutic opportu

295 represents a novel therapeutic strategy for cardioprotection with great potential clinical utility.

296 R injury demonstrated significant functional cardioprotection with reduced myofibroblast transformati

297 Additionally, we contemplated that cardioprotection with tadalafil is mediated by hydrogen

298 ncy of heart-targeted delivery and effective cardioprotection with this combination approach.

299 Dexrazoxane provides long-term cardioprotection without compromising oncological effica

300 emical changes in isolation, to suggest that cardioprotection would necessarily follow; rather, direc